CHMP Adopts Positive Opinion For Deciphera's Qinlock To Treat Gastrointestinal Stromal Tumor

(RTTNews) - Deciphera Pharmaceuticals Inc. (DCPH) said that the European Medicines Agency's or EMA Committee for Medicinal Products for Human Use or CHMP has adopted a positive opinion recommending the approval of Qinlock or ripretinib for the treatment of adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with three or more kinase inhibitors, including imatinib.

The positive CHMP opinion is a scientific recommendation for marketing authorization and one of the final steps before the European Commission. The European Commission has the authority to approve medicines in the European Union (EU), issues a decision on Deciphera's marketing authorization application (MAA) for ripretinib.

The European Commission decision is anticipated by the fourth quarter of 2021.